ThromboGenics NV is a biopharmaceutical company, which engages in developing and commercializing medicines for the treatment of vitreo retinal diseases. It operates under JETREA (ocriplasmin) brand name. The company was founded in 1991 by Desire Collen and is headquartered in Leuven, Belgium.
Comparing the value of the Australian share market as a whole with global indices can be a dangerous and futile exercise. After all, most investors are individual stock-pickers not index huggers. However, once you recognise exactly how top-heavy the ASX is compared to the US and other global markets, you’ll sit up and take notice when analysts have concerns over valuations.